Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01398904 · ClinicalTrials.gov registry record
Attentional Bias in Body Dysmorphic Disorder
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 51
- Enrollment target
NCT01398904: Completed study, sponsored by Massachusetts General Hospital.
NCT01398904 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 51 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01398904 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 51 participants
- Enrollment target
Study Summary
Body Dysmorphic Disorder (BDD) participants will demonstrate greater attentional biases as compared to healthy control (HC) participants. Greater attention bias will be associated with greater distress. Greater attention bias will be associated with greater symptom severity.
Primary Outcome
Gaze tracking via an Eyelink II eye tracker will determine perception of visual information.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2011-03 |
| Est. Completion | 2012-07 |
What the finished NCT01398904 record still lists
NCT01398904 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 51 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01398904 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01398904 about?
NCT01398904 is a clinical study titled "Attentional Bias in Body Dysmorphic Disorder". Body Dysmorphic Disorder (BDD) participants will demonstrate greater attentional biases as compared to healthy control (HC) participants. Greater attention bias will be associated with greater distress. Greater attention bias will be associated with greater symptom severity.
What is the current status of trial NCT01398904?
This trial is currently completed. The enrollment target is 51 participants. The study started on 2011-03. Estimated completion is 2012-07.
Who is sponsoring clinical trial NCT01398904?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia